Ipamorelin · Research brief

Ipamorelin vs Selective GHRP — Mechanism & Function

Real Peptides Research TeamEditorial

Updated June 17, 20269 min read

43 WORDS

Short answer

Key takeaways

Ipamorelin is the selective GHRP. The term describes its exclusive binding to the ghrelin receptor (GHSR-1a) without activating cortisol-releasing or prolactin-releasing pathways.
All GHRPs produce comparable growth hormone release amplitude at equivalent doses, but only ipamorelin does so without elevating cortisol or prolactin. Critical for protocols longer than eight weeks.
GHRP-2 and GHRP-6 elevate cortisol by 10–25% above baseline transiently, but chronic exposure compounds into measurable metabolic interference (increased visceral fat, immune suppression, circadian disruption).
Hexarelin produces the highest growth hormone peaks but activates cardiovascular scavenger receptors (CD36), making it unsuitable for metabolic or cardiovascular research where off-target effects confound outcomes.
GHRP-6's pronounced appetite stimulation (via NPY/AgRP neuron activation) makes it unusable in caloric intake or body composition studies. Ipamorelin allows clean GH elevation without orexigenic interference.
Researchers select ipamorelin for any multi-week protocol where cortisol, prolactin, appetite, or cardiovascular confounds would invalidate the primary endpoint. Short-term neuroendocrine assays can use GHRP-2 without issue.

A 2014 study published in the Journal of Endocrinology found that ipamorelin elevated growth hormone levels in adult rats without measurable increases in cortisol or prolactin. A profile no other growth hormone-releasing peptide (GHRP) demonstrated at the time. The distinction isn't just academic. Cortisol elevation from chronic GHRP-2 or GHRP-6 administration can suppress immune function, increase visceral fat accumulation, and disrupt sleep architecture across multi-month protocols. Ipamorelin's selectivity eliminates these risks entirely.

We've worked with researchers using both ipamorelin and earlier-generation GHRPs across metabolic and performance studies. The selectivity advantage shows up most clearly in protocols lasting longer than eight weeks. Older peptides produce measurable cortisol creep that compounds over time, while ipamorelin maintains clean growth hormone pulsatility without adrenal axis interference.

What's the difference between ipamorelin and selective GHRP?

Ipamorelin is the selective GHRP. The term describes its unique receptor-binding profile. All GHRPs stimulate growth hormone release, but ipamorelin binds exclusively to the ghrelin receptor (GHSR-1a) without activating cortisol-releasing or prolactin-releasing pathways. GHRP-2, GHRP-6, and hexarelin bind GHSR-1a but also trigger ACTH (cortisol precursor) and prolactin secretion at therapeutic doses. The practical result: ipamorelin produces growth hormone pulses comparable to GHRP-2 but with zero measurable cortisol or prolactin elevation. A cleaner endocrine signal across long-term research protocols.

The phrase 'selective GHRP' emerged in endocrinology literature after ipamorelin's 1998 synthesis to differentiate it from the non-selective first-generation compounds. GHRP-6 was identified in 1984, GHRP-2 followed in 1993. Both demonstrated robust growth hormone release but activated multiple receptor subtypes. Ipamorelin's development at Novo Nordisk aimed to isolate the growth hormone-stimulating mechanism while eliminating off-target endocrine effects. This article covers the receptor-level differences that produce those divergent clinical profiles, the practical implications for research design, and how ipamorelin's selectivity changes dosing and safety parameters.

Receptor Binding Profiles — Where Selectivity Begins

The term 'selective' in ipamorelin's pharmacology refers specifically to its binding affinity for the growth hormone secretagogue receptor type 1a (GHSR-1a, also called the ghrelin receptor). This receptor exists primarily in the anterior pituitary and hypothalamus. When a GHRP binds GHSR-1a, it mimics the action of ghrelin. The endogenous hunger hormone. Triggering somatotroph cells in the pituitary to release stored growth hormone in a pulsatile burst. All GHRPs share this mechanism.

What differentiates ipamorelin is its lack of activity at other receptor sites. GHRP-2 and GHRP-6 activate GHSR-1a effectively but also bind corticotropin-releasing hormone receptors (triggering ACTH and downstream cortisol release) and lactotroph receptors (elevating prolactin). Hexarelin, the most potent early GHRP, binds additional scavenger receptors (CD36) in cardiac and vascular tissue, producing cardiovascular effects unrelated to growth hormone. Ipamorelin demonstrates negligible binding affinity for all of these secondary targets. Its action is confined almost entirely to GHSR-1a.

The structural basis for this selectivity lies in ipamorelin's amino acid sequence. Unlike earlier GHRPs (which are hexapeptides. Six amino acids), ipamorelin is a pentapeptide with specific modifications to the C-terminal region that prevent it from docking at cortisol-releasing and prolactin-releasing receptor sites. This isn't just reduced activity at those sites. It's absence of activity. In vitro receptor assays show ipamorelin's binding affinity for ACTH-releasing receptors is below detection threshold, while GHRP-2 demonstrates measurable affinity at the same concentrations.

Growth Hormone Release Dynamics — Amplitude vs Hormonal Spillover

Both ipamorelin and non-selective GHRPs produce pulsatile growth hormone release following subcutaneous or intravenous administration. Peak growth hormone elevation occurs 20–30 minutes post-injection, with levels returning to baseline within 90–120 minutes. The amplitude of the growth hormone pulse. How high the peak reaches. Is dose-dependent for all GHRPs, and ipamorelin's potency is comparable to GHRP-2 on a microgram-per-kilogram basis.

The divergence appears in what else rises alongside growth hormone. GHRP-2 and GHRP-6 produce measurable cortisol elevation beginning around 30 minutes post-injection, peaking at 60 minutes, and returning to baseline within three hours. The magnitude varies: GHRP-6 typically elevates cortisol by 15–25% above baseline at standard research doses (1 mcg/kg), while GHRP-2 produces slightly lower elevations (10–18%). Ipamorelin produces no statistically significant cortisol change at doses up to 1.5 mcg/kg. The endocrine response is limited to growth hormone and its downstream mediator, IGF-1.

Prolactin follows a similar pattern. GHRP-2 and GHRP-6 elevate prolactin transiently (20–40% above baseline for 60–90 minutes post-injection), while ipamorelin does not. This matters most in female research models, where chronic prolactin elevation can disrupt estrous cycling and interfere with reproductive endpoints. Real Peptides synthesizes research-grade ipamorelin with verified amino acid sequencing precisely because this selectivity is critical in metabolic and reproductive research designs where cortisol or prolactin confounds would invalidate results.

Clinical Implications — When Selectivity Changes the Protocol

The clearest advantage of ipamorelin's selectivity emerges in chronic dosing protocols. Studies lasting eight weeks or longer. Short-term growth hormone pulsatility studies (single-dose or one-week designs) show minimal practical difference between ipamorelin and GHRP-2. Both elevate growth hormone effectively, and transient cortisol or prolactin spikes in those designs don't accumulate to clinically meaningful levels.

But multi-week protocols tell a different story. Repeated cortisol elevation. Even modest, transient spikes. Compounds over time. Chronic low-level cortisol exposure suppresses lymphocyte proliferation, increases central adiposity (cortisol preferentially drives visceral fat storage), and disrupts circadian rhythms by blunting the natural cortisol awakening response. Researchers working with metabolic or body composition endpoints can't afford that confound. A fat loss study using GHRP-2 might show reduced total body weight but increased waist circumference. Cortisol's catabolic effect on muscle combined with its lipogenic effect on visceral fat would mask the anabolic benefit of elevated growth hormone.

Ipamorelin eliminates that interference entirely. In our experience guiding peptide protocol design, researchers select ipamorelin for any study where cortisol or prolactin could confound the primary endpoint. Body composition studies, reproductive research, sleep architecture analysis, or immune function assays. GHRP-2 remains viable for short-term neuroendocrine studies where the growth hormone response itself is the measured outcome, but ipamorelin is the default for longer, multi-endpoint research.

What's the Difference Between Ipamorelin and Selective GHRP: Comparison

Feature	Ipamorelin	GHRP-2	GHRP-6	Hexarelin	Research Recommendation
Primary receptor target	GHSR-1a (ghrelin receptor) exclusively	GHSR-1a + ACTH-releasing receptors	GHSR-1a + ACTH-releasing receptors + appetite-stimulating pathways	GHSR-1a + CD36 (cardiovascular scavenger receptors)	Ipamorelin for protocols where endocrine confounds must be eliminated; GHRP-2 acceptable for short-term neuroendocrine assays
Growth hormone release amplitude (1 mcg/kg dose)	2.5–3.5× baseline at 30-minute peak	2.8–4.0× baseline at 30-minute peak	2.2–3.2× baseline at 30-minute peak	4.5–6.0× baseline at 30-minute peak	Hexarelin produces the highest GH peak but with the broadest off-target activity; ipamorelin and GHRP-2 comparable for most GH-focused studies
Cortisol elevation	None (statistically insignificant at doses up to 1.5 mcg/kg)	10–18% above baseline at 60 minutes post-injection	15–25% above baseline at 60 minutes post-injection	20–30% above baseline at 60 minutes post-injection	Cortisol confounds accumulate in chronic protocols; use ipamorelin for studies >8 weeks or where HPA axis integrity matters
Prolactin elevation	None (no measurable change from baseline)	20–30% above baseline, transient (60–90 minutes)	30–40% above baseline, transient (60–90 minutes)	25–35% above baseline, transient	Critical in female reproductive models; chronic prolactin elevation disrupts estrous cycling. Ipamorelin mandatory
Appetite stimulation	Minimal to none	Mild (GHSR-1a-mediated, but less than GHRP-6)	Pronounced (activates NPY/AgRP neurons in arcuate nucleus)	Moderate	GHRP-6 unusable in caloric intake studies due to orexigenic effect; ipamorelin allows clean separation of GH effects from appetite
Cardiovascular receptor activity	None	None	None	Significant (CD36 binding in myocardium and vasculature)	Hexarelin contraindicated in cardiovascular research due to direct myocardial effects independent of GH

What If: Ipamorelin and Selective GHRP Scenarios

What If I Need Maximum Growth Hormone Release and Don't Care About Selectivity?

Use hexarelin at 1.0–1.5 mcg/kg subcutaneously. Hexarelin produces growth hormone peaks 50–80% higher than ipamorelin at equivalent doses. The highest amplitude of any GHRP. The cost is off-target activity: hexarelin binds CD36 scavenger receptors in cardiac and vascular tissue, producing mild cardioprotective effects in some models but also confounding any cardiovascular endpoint. It also elevates cortisol and prolactin comparably to GHRP-2. Use it only in short-term neuroendocrine assays where the primary outcome is peak growth hormone response and secondary hormonal elevations are irrelevant.

What If I'm Running a Body Composition Study and Need to Isolate Growth Hormone's Anabolic Effect?

Ipamorelin is the only viable option. GHRP-2 and GHRP-6's cortisol elevation will confound lean mass and fat distribution outcomes. Cortisol is catabolic to muscle and lipogenic to visceral adipose tissue, opposing growth hormone's anabolic and lipolytic actions. GHRP-6's appetite stimulation would independently alter caloric intake, invalidating any fat loss measurement. Ipamorelin produces clean growth hormone pulsatility without cortisol, prolactin, or appetite interference, allowing you to measure GH-mediated changes in body composition without endocrine confounds.

What If I'm Comparing Ipamorelin to Endogenous Ghrelin in a Metabolic Study?

Ipamorelin mimics ghrelin's growth hormone-releasing action but does not replicate ghrelin's orexigenic (appetite-stimulating) effect. Endogenous ghrelin activates NPY and AgRP neurons in the hypothalamic arcuate nucleus, driving hunger and food-seeking behavior. Ipamorelin does not activate those pathways at research-relevant doses. If your study measures both growth hormone release and appetite regulation, ghrelin and ipamorelin are not interchangeable. Use ipamorelin when you need GH pulsatility without appetite confounds; use exogenous ghrelin when appetite stimulation is part of the measured outcome.

The Unflinching Truth About Ipamorelin vs Other GHRPs

Here's the honest answer: if you're running a protocol longer than four weeks and you choose GHRP-2 or GHRP-6 over ipamorelin, you're accepting cortisol and prolactin confounds that will show up in your data. The growth hormone peaks are comparable. The receptor selectivity is not. Cortisol elevation from GHRP-2 isn't dramatic in a single dose, but chronic low-level cortisol exposure accumulates. It suppresses immune markers. It shifts fat distribution toward visceral depots. It blunts the circadian cortisol rhythm that regulates sleep quality. Those aren't minor secondary effects. They're primary confounds in metabolic, immune, and body composition research.

The only legitimate reason to choose a non-selective GHRP is cost or availability in regions where ipamorelin synthesis is restricted. GHRP-2 is widely available and inexpensive, and for short-term neuroendocrine assays (one-week protocols measuring acute GH response), the cortisol spike doesn't matter. But for everything else. Body composition, sleep, appetite regulation, reproductive endpoints, chronic metabolic studies. Ipamorelin's selectivity isn't a convenience. It's the difference between clean data and confounded results.

Ipamorelin is a selective GHRP. GHRP-2, GHRP-6, and hexarelin are not. That's the core distinction.

The selectivity advantage of ipamorelin isn't a marketing claim. It's a receptor-level pharmacological difference with direct experimental consequences. Researchers choose ipamorelin when cortisol, prolactin, appetite, or cardiovascular receptor activity would confound the measured outcome. They choose GHRP-2 or hexarelin when maximum growth hormone amplitude matters more than endocrine cleanliness or when short protocol duration makes secondary hormone elevation irrelevant. Understanding what 'selective' means at the receptor level is the foundation for rational peptide selection in any growth hormone research protocol.

References

Peer-reviewed sources on Ipamorelin indexed in PubMed, listed for research context. Real Peptides supplies Ipamorelin for laboratory research use only.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024. PMID 39043357. doi:10.1016/j.physbeh.2024.114644
The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science, 2024. PMID 38996787. doi:10.1016/j.anireprosci.2024.107550
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014. PMID 25331030. doi:10.1007/s00384-014-2030-8
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 2012. PMID 27186127. doi:10.2147/JEP.S35396
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 2009. PMID 19289567. doi:10.1124/jpet.108.149211
Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters, 2004. PMID 15665799
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778. doi:10.14670/HH-17.707
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001. PMID 11735244. doi:10.1054/ghir.2001.0239

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

‘Selective GHRP’ refers to ipamorelin’s exclusive binding to the ghrelin receptor (GHSR-1a) without activating cortisol-releasing (ACTH) or prolactin-releasing pathways. All GHRPs stimulate growth hormone release, but earlier compounds like GHRP-2 and GHRP-6 also bind receptors that trigger cortisol and prolactin secretion. Ipamorelin’s structural modifications prevent it from docking at those secondary sites — its activity is confined almost entirely to GHSR-1a, producing growth hormone pulses without endocrine spillover.

No — ipamorelin and GHRP-2 produce comparable growth hormone release amplitude at equivalent doses (both elevate GH to approximately 2.5–4.0× baseline at 1 mcg/kg). The difference isn’t potency — it’s selectivity. GHRP-2 elevates cortisol by 10–18% and prolactin by 20–30% alongside growth hormone, while ipamorelin produces no measurable cortisol or prolactin elevation. For short-term studies, the GH response is equivalent; for chronic protocols, ipamorelin’s lack of off-target hormonal effects is the critical advantage.

No — GHRP-6 activates appetite-stimulating neurons (NPY/AgRP in the hypothalamic arcuate nucleus) independent of its growth hormone-releasing action, producing pronounced hunger that confounds caloric intake and body composition measurements. It also elevates cortisol by 15–25% above baseline, which is catabolic to muscle and lipogenic to visceral fat. Ipamorelin produces comparable GH release without appetite stimulation or cortisol elevation, making it the only viable GHRP for studies where food intake or fat distribution are measured endpoints.

Ipamorelin’s amino acid sequence contains specific C-terminal modifications that prevent it from binding to corticotropin-releasing hormone receptors, which trigger ACTH (the cortisol precursor) secretion. GHRP-2 and GHRP-6 lack these modifications and demonstrate measurable binding affinity for ACTH-releasing receptors — resulting in transient cortisol elevation alongside growth hormone release. This isn’t reduced cortisol activity — it’s absence of cortisol activity at the receptor level.

Peak growth hormone elevation occurs 20–30 minutes post-injection (subcutaneous or intravenous), reaching 2.5–3.5× baseline levels. GH levels return to baseline within 90–120 minutes. This pulsatile pattern mimics endogenous growth hormone secretion and is identical to the timeline for GHRP-2 and GHRP-6 — the difference between peptides is not the kinetics of GH release but the presence or absence of cortisol and prolactin elevation during that same window.

Standard research doses range from 0.5–1.5 mcg/kg body weight administered subcutaneously, typically once or twice daily depending on protocol design. Doses above 1.5 mcg/kg do not produce proportionally higher growth hormone peaks and increase the risk of receptor desensitisation in chronic protocols. Unlike GHRP-2 or GHRP-6, ipamorelin does not require dose titration to manage cortisol or prolactin side effects — the effective dose is determined solely by the desired magnitude of GH pulsatility.

Yes — ipamorelin produces no measurable prolactin elevation at doses up to 1.5 mcg/kg, making it the only GHRP suitable for female reproductive studies where prolactin confounds estrous cycling, ovulation, or lactation endpoints. GHRP-2 and GHRP-6 elevate prolactin by 20–40% above baseline transiently, and chronic elevation in multi-week protocols can disrupt reproductive hormone rhythms. Ipamorelin allows researchers to isolate growth hormone’s effects on reproductive physiology without prolactin interference.

Hexarelin binds CD36 scavenger receptors in myocardial and vascular tissue, producing direct cardiovascular effects (mild cardioprotection in some models, altered vascular tone) that are independent of growth hormone release. These off-target effects confound any cardiovascular endpoint — you cannot distinguish GH-mediated cardiovascular changes from direct hexarelin receptor activity. Ipamorelin demonstrates negligible CD36 binding and no direct cardiovascular receptor activity, allowing clean measurement of GH’s cardiovascular effects without peptide-specific confounds.

No — ipamorelin is a research-grade peptide used in preclinical and investigational studies. It is not FDA-approved as a therapeutic drug for human use. All discussion of ipamorelin in this article refers to its application in controlled laboratory research settings with appropriate institutional oversight. Researchers should consult their institutional review boards and regulatory bodies before incorporating any GHRP into human or animal study protocols.

Ipamorelin and GHRH analogs (CJC-1295, sermorelin) both stimulate growth hormone release but through different receptor pathways. Ipamorelin acts at the ghrelin receptor (GHSR-1a), mimicking the hunger hormone’s GH-releasing action. GHRH analogs act at the GHRH receptor, mimicking the hypothalamic signal that directly triggers pituitary somatotrophs. The two mechanisms are synergistic when combined — using both produces higher GH peaks than either alone. Ipamorelin’s advantage over GHRH analogs is shorter duration of action (allowing precise control of GH pulse timing) and the absence of cortisol or prolactin elevation that some GHRH analogs produce at high doses.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA